Dec. 4 at 4:19 PM
$INSM from IV, Rothschild & Co Redburn🏁
$INSM Buy/
$263
$LQDA $UTHR
Rothschild & Co Redburn said—Insmed is well positioned in large therapy areas with limited competition. With the recent approvals of Brinsupri, a first-in-class therapy for bronchiectasis, we anticipate strong uptake given the lack of competitors.
Along with potential indication expansion opportunities, we believe Brinsupri has peak sales of c
$12BN, above the consensus median of c
$10BN.
TPIP is the next important growth driver with multi-billion-dollar blockbuster potential. We launch coverage of Insmed with a Buy recommendation and a
$263 price target.
